Mylan, Inc. (MYL)
-NasdaqGS 31.40 
0.70(2.28%) May 17, 4:00PM EDT|After Hours
:
31.42 0.02 (0.07%) May 17, 4:42PM EDT
| Prev Close: | 30.70 |
|---|
| Open: | 30.90 |
|---|
| Bid: | 31.03 x 300 |
|---|
| Ask: | 31.79 x 300 |
|---|
| 1y Target Est: | 32.03 |
|---|
| Beta: | 1.21 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 30.84 - 31.47 |
|---|
| 52wk Range: | 20.50 - 31.47 |
|---|
| Volume: | 5,720,298 |
|---|
| Avg Vol (3m): | 6,186,660 |
|---|
| Market Cap: | 11.97B |
|---|
| P/E (ttm): | 20.98 |
|---|
| EPS (ttm): | 1.50 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Warner Chilcott buy may be Actavis' best takeover defenseat Reuters(Fri, May 17)
- DEALTALK: Warner Chilcott buy may be Actavis' best takeover defenseat Reuters(Fri, May 17)
- Mylan attracts bulls at all-time highsoptionMONSTER(Fri, May 17)
- InPlay: Mylan Labs launches generic version of Abbvie's (ABBV) Tricor TabletsBriefing.com(Fri, May 17)
- Mylan Launches Generic Tricor® TabletsPR Newswire(Fri, May 17)
- Drugmaker Actavis' shares upAP(Thu, May 16)
- Novartis says has no intention of buying Actavisat Reuters(Thu, May 16)
- Ahead of the Bell: Drugmaker Actavis' shares upAP(Thu, May 16)
- What WSJ Canada Is Reading Thursdayat The Wall Street Journal(Thu, May 16)
- Early Movers: WMT, KSS, CSCO & Moreat CNBC(Thu, May 16)
- The Morning Ledger: New Proposal Aims to Overhaul Lease-Accounting Rulesat The Wall Street Journal(Thu, May 16)
- Actavis - A Potential Deal With Warner Chilcott Would Further Spur Interest In Actavis Itselfat Seeking Alpha(Thu, May 16)
- [$$] Drug Firms Stalk Actavisat The Wall Street Journal(Wed, May 15)
- 4 Healthcare Stock Stories Prescribed for Investorsat Wall St. Cheat Sheet(Wed, May 15)
- Mylan: Solid Results Despite Revenue Missat Seeking Alpha(Wed, May 15)
Key Statistics
| Forward P/E (1 yr): | 9.72 |
|---|
| P/S (ttm): | 1.71 |
|---|
| Ex-Dividend Date: | 27-Jun-07 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 2.86 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.67 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | 1.22 |
|---|
Business Summary
Mylan Inc. engages in the development, manufacture, marketing, licensing, and distribution of generic and branded generic pharmaceuticals, specialty pharmaceuticals, and active pharmaceutical ingredients (APIs) worldwide.
View More